Lenvima (lenvatinib; Eisai/Merck & Co) Drug Overview 2019

Figure 1: The author's drug assessment summary of Lenvima for HCC
Figure 2: The author's drug assessment summary of Lenvima for HCC
Figure 3: Lenvima sales for HCC across the US, Japan, and five major EU markets, by country, 2018–27
Figure 4: Lenvima for RCC – SWOT analysis
Figure 5: The author's drug assessment summary of Lenvima for RCC
Figure 6: The author's drug assessment summary of Lenvima for RCC
Figure 7: Lenvima sales for RCC across the US, Japan, and five major EU markets, by country, 2017–26

Table 1: Recent high-impact events for Lenvima in HCC
Table 2: Lenvima drug profile
Table 3: Approval history of Lenvima for HCC in the US, Japan, and five major EU markets
Table 4: Trials of Lenvima for HCC
Table 5: Lenvima for HCC – SWOT analysis
Table 6: Lenvima drug profile
Table 7: Lenvima pivotal trial data in RCC
Table 8: Lenvima ongoing trials in RCC
Table 9: Lenvima sales for RCC across the US, Japan, and five major EU markets, by country ($m), 2017–26